Pluvicto Therapy is an advanced PSMA-targeted treatment designed for metastatic prostate cancer patients.
This cutting-edge Lutetium-177 (Lu-177) radiopharmaceutical therapy delivers radiation directly to cancer cells, improving survival outcomes while minimizing damage to healthy tissues.
It is especially beneficial for patients who have not responded to conventional treatments like chemotherapy or hormone therapy.
Consult our expert in Delhi for safe, personalized, and effective Pluvicto therapy.
Pluvicto Therapy is an FDA-approved PSMA-based targeted treatment for advanced prostate cancer. It uses a radioligand that binds to PSMA proteins on cancer cells and delivers precise radiation therapy directly to tumors.
PSMA proteins are identified on prostate cancer cells.
Pluvicto binds specifically to PSMA-positive cancer cells.
Lutetium-177 delivers targeted radiation directly to tumors.
Cancer cells are destroyed from within while sparing healthy tissue.
Pluvicto therapy in Delhi is recommended for:
Take the next step toward advanced prostate cancer treatment.
Directly targets PSMA-positive prostate cancer cells with precision.
Clinically proven to extend survival in advanced prostate cancer.
Works well in patients with metastatic or resistant prostate cancer.
Targeted approach reduces damage to healthy tissues.
Helps reduce symptoms and improves daily living.
The cost of Pluvicto therapy depends on:
For accurate pricing, book a consultation in Delhi.
Book ConsultationPluvicto therapy is generally well-tolerated, but mild side effects may include:
Side effects are manageable with proper medical care.
Pluvicto therapy is a type of PSMA-targeted Lutetium therapy, specifically approved for advanced prostate cancer. It offers more standardized and clinically proven treatment outcomes compared to general PSMA therapies.
